The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 20, 2017
Filed:
Nov. 04, 2014
Applicant:
Ube Industries, Ltd., Ube-shi, JP;
Inventors:
Shigeyoshi Nishino, Ube, JP;
Hidetaka Shima, Ube, JP;
Hiroyuki Oda, Ube, JP;
Tetsuro Shimano, Ube, JP;
Assignee:
UBE INDUSTRIES, LTD., Ube-Shi, JP;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/167 (2006.01); A61K 31/216 (2006.01); A61K 31/36 (2006.01); C07C 381/00 (2006.01); C07D 207/327 (2006.01); C07D 207/34 (2006.01); C07D 213/81 (2006.01); C07D 213/82 (2006.01); C07D 231/12 (2006.01); C07D 231/14 (2006.01); C07D 233/90 (2006.01); C07D 237/24 (2006.01); C07D 239/28 (2006.01); C07D 239/34 (2006.01); C07D 241/24 (2006.01); C07D 263/34 (2006.01); C07D 277/56 (2006.01); C07D 307/68 (2006.01); C07D 311/16 (2006.01); C07D 317/60 (2006.01); C07D 333/38 (2006.01);
U.S. Cl.
CPC ...
C07C 381/00 (2013.01); A61K 31/167 (2013.01); A61K 31/216 (2013.01); A61K 31/36 (2013.01); C07D 207/327 (2013.01); C07D 207/34 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07D 231/12 (2013.01); C07D 231/14 (2013.01); C07D 233/90 (2013.01); C07D 237/24 (2013.01); C07D 239/28 (2013.01); C07D 239/34 (2013.01); C07D 241/24 (2013.01); C07D 263/34 (2013.01); C07D 277/56 (2013.01); C07D 307/68 (2013.01); C07D 311/16 (2013.01); C07D 317/60 (2013.01); C07D 333/38 (2013.01);
Abstract
An aryloyl(oxy or amino)pentafluorosulfanylbenzene compound having pharmacological action. The aryloyl(oxy or amino)pentafluorosulfanylbenzene compound is represented by general formula (A-I), a pharmaceutically acceptable salt thereof, and a prodrug thereof, wherein all of parameters represent the same meanings as defined in the specification.